Nanobiotix Reports Share Capital and Voting Rights
Biotechnology firm Nanobiotix released figures for its share capital and voting rights as of May 2026. The company is listed on both Euronext Paris and Nasdaq.
Biotechnology company Nanobiotix has disclosed its share capital and voting rights figures as of the end of May 2026. The company is incorporated in France and maintains listings on both Euronext Paris and the Nasdaq Global Select Market.
According to the disclosure, Nanobiotix had 50,807,903 shares outstanding on May 31, 2026. The total number of theoretical voting rights stood at 54,304,858, with 54,282,740 exercisable voting rights.
Nanobiotix is a late-stage clinical biotechnology firm focused on physics-based therapeutic approaches, aiming to disrupt treatment outcomes for patients, particularly in oncology. The company's work is supported by a dedicated team focused on advancing human health possibilities through scientific innovation.
Established in 2003 and headquartered in Paris, Nanobiotix also operates a subsidiary in Cambridge, Massachusetts. The company holds more than 30 patent families related to three nanotechnology platforms, with applications spanning oncology, bioavailability and biodistribution, and central nervous system disorders.